Sean Hawkey1,2, Grace J Young3, Paul Little4, Michael Moore4, Alastair D Hay5,2. 1. Center for Academic Primary Care, National Institute for Health Research (NIHR) School for Primary Care Research, Bristol Medical School, University of Bristol, Bristol, UK. 2. Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 3. Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK. 4. Primary Care and Population Science, NIHR School for Primary Care Research, Aldermoor Health Centre, University of Southampton, Southampton, UK. 5. Center for Academic Primary Care, National Institute for Health Research (NIHR) School for Primary Care Research, Bristol Medical School, University of Bristol, Bristol, UK alastair.hay@bristol.ac.uk.
Abstract
BACKGROUND: Acute lower respiratory tract infection (ALRTI) is often treated in primary care with antibiotics. The recent Oral Steroids for Acute Cough (OSAC) randomised controlled trial (RCT) showed corticosteroids were not an effective alternative in adults without a diagnosis of asthma with ALRTI. AIM: To investigate if corticosteroids are beneficial for ALRTI in patients with unrecognised asthma. DESIGN & SETTING: An exploratory analysis was undertaken of the primary care OSAC trial. METHOD: A subgroup analysis was performed in patients who responded 'yes' to the following International Primary Care Airways Group (IPCAG) question: did you have wheeze and/or at least two of nocturnal cough or chest tightness or dyspnoea in the past year. Sensitivity analyses were carried out on those who answered 'yes' to wheeze and at least two of the nocturnal symptoms. The primary outcomes were as follows: duration of cough (0-28 days, minimum clinically important difference [MCID] of 3.79 days) and mean symptom severity score (range 0-6; MCID 1.66 units). RESULTS: In total, 40 (10%) patients were included in the main analysis: mean age 49 years (standard deviation [SD] = 17.9), 52% male. Median cough duration was 3 days in both prednisolone (interquartile range [IQR] = 2-6 days) and placebo (IQR = 1-6 days) groups (adjusted hazard ratio [HR] = 1.10; 95% confidence interval [CI] = 0.47 to 2.54; P = 0.83), equating to 0.24 days longer in the prednisolone group (95% CI = 1.23 days shorter to 2.88 days longer). Mean symptom severity difference was -0.14 (95% CI = -0.78 to 0.49; P=0.65) comparing prednisolone with placebo. Similar findings were found in the sensitivity analysis. CONCLUSION: No evidence was found to support the use of corticosteroids for ALRTI in patients with clinically unrecognised asthma. Clinicians should not use the IPCAG questions to target oral corticosteroid treatment in patients with ALRTI.
RCT Entities:
BACKGROUND: Acute lower respiratory tract infection (ALRTI) is often treated in primary care with antibiotics. The recent Oral Steroids for Acute Cough (OSAC) randomised controlled trial (RCT) showed corticosteroids were not an effective alternative in adults without a diagnosis of asthma with ALRTI. AIM: To investigate if corticosteroids are beneficial for ALRTI in patients with unrecognised asthma. DESIGN & SETTING: An exploratory analysis was undertaken of the primary care OSAC trial. METHOD: A subgroup analysis was performed in patients who responded 'yes' to the following International Primary Care Airways Group (IPCAG) question: did you have wheeze and/or at least two of nocturnal cough or chest tightness or dyspnoea in the past year. Sensitivity analyses were carried out on those who answered 'yes' to wheeze and at least two of the nocturnal symptoms. The primary outcomes were as follows: duration of cough (0-28 days, minimum clinically important difference [MCID] of 3.79 days) and mean symptom severity score (range 0-6; MCID 1.66 units). RESULTS: In total, 40 (10%) patients were included in the main analysis: mean age 49 years (standard deviation [SD] = 17.9), 52% male. Median cough duration was 3 days in both prednisolone (interquartile range [IQR] = 2-6 days) and placebo (IQR = 1-6 days) groups (adjusted hazard ratio [HR] = 1.10; 95% confidence interval [CI] = 0.47 to 2.54; P = 0.83), equating to 0.24 days longer in the prednisolone group (95% CI = 1.23 days shorter to 2.88 days longer). Mean symptom severity difference was -0.14 (95% CI = -0.78 to 0.49; P=0.65) comparing prednisolone with placebo. Similar findings were found in the sensitivity analysis. CONCLUSION: No evidence was found to support the use of corticosteroids for ALRTI in patients with clinically unrecognised asthma. Clinicians should not use the IPCAG questions to target oral corticosteroid treatment in patients with ALRTI.
Authors: Roderick P Venekamp; Marc J M Bonten; Maroeska M Rovers; Theo J M Verheij; Alfred P E Sachs Journal: CMAJ Date: 2012-08-07 Impact factor: 8.262
Authors: Michael Moore; Beth Stuart; Samuel Coenen; Chris C Butler; Herman Goossens; Theo J M Verheij; Paul Little Journal: Br J Gen Pract Date: 2014-02 Impact factor: 5.386
Authors: Paul Little; Kate Rumsby; Joanne Kelly; Louise Watson; Michael Moore; Gregory Warner; Tom Fahey; Ian Williamson Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Paul Little; Beth Stuart; Michael Moore; Samuel Coenen; Christopher C Butler; Maciek Godycki-Cwirko; Artur Mierzecki; Slawomir Chlabicz; Antoni Torres; Jordi Almirall; Mel Davies; Tom Schaberg; Sigvard Mölstad; Francesco Blasi; An De Sutter; Janko Kersnik; Helena Hupkova; Pia Touboul; Kerenza Hood; Mark Mullee; Gilly O'Reilly; Curt Brugman; Herman Goossens; Theo Verheij Journal: Lancet Infect Dis Date: 2012-12-19 Impact factor: 25.071
Authors: Alastair D Hay; Paul Little; Anthony Harnden; Matthew Thompson; Kay Wang; Denise Kendrick; Elizabeth Orton; Sara T Brookes; Grace J Young; Margaret May; Sandra Hollinghurst; Fran E Carroll; Harriet Downing; David Timmins; Natasher Lafond; Magdy El-Gohary; Michael Moore Journal: JAMA Date: 2017-08-22 Impact factor: 56.272
Authors: C J Trigg; K G Nicholson; J H Wang; D C Ireland; S Jordan; J M Duddle; S Hamilton; R J Davies Journal: Clin Exp Allergy Date: 1996-06 Impact factor: 5.018